Allan JN et al. Treatment outcomes after undetectable MRD with first-line ibrutinib (ibr) plus venetoclax (ven): fixed duration treatment (placebo) versus continued ibr with up to 5 years median follow-up in the CAPTIVATE study. ASH 2022;Abstract 92.
Brown JR et al. Zanubrutinib demonstrates superior progression-free survival (PFS) compared with ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): Results from final analysis of ALPINE randomized phase 3 study. ASH 2022;Abstract LBA-6.
Byrd JC et al. Final results of the phase 1/2 study of acalabrutinib monotherapy in treatment-naive chronic lymphocytic leukemia with >6 years of follow-up. ASH 2022;Abstract 4431.
Cheah CY et al. A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor Bgb-11417 as monotherapy or in combination with zanubrutinib (ZANU) in patients (pts) with CLL/SLL: Preliminary data. ASH 2022;Abstract 962.
Davids MS et al. Contribution of obinutuzumab to acalabrutinib therapy in patients with treatment-naive chronic lymphocytic leukemia: Analysis of survival outcomes by genomic features. ASH 2022;Abstract 1815.
Davids MS et al. Lisaftoclax (APG-2575) safety and activity as monotherapy or combined with acalabrutinib or rituximab in patients (pts) with treatment-naïve, relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL): Initial data from a phase 2 global study. ASH 2022;Abstract 964.
Jacobs R et al. Real-world comparison of time to next treatment for patients with CLL initiated on first-line treatment with ibrutinib versus acalabrutinib. ASH 2022;Abstract 797.
Kater AP et al. Subcutaneous epcoritamab in patients with Richter’s syndrome: Early results from phase 1b/2 trial (EPCORE CLL-1). ASH 2022;Abstract 348.
Mato AR et al. Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory CLL/SLL: Additional patients and extended follow-up from the phase 1/2 BRUIN study. ASH 2022;Abstract 961.
Munir T et al. Combination of ibrutinib plus venetoclax with MRD-driven duration of treatment results in a higher rate of MRD negativity in IGHV unmutated than mutated CLL: Updated interim analysis of FLAIR study. ASH 2022;Abstract 94.
Niemann CU et al. Residual disease kinetics among patients with high-risk factors treated with first-line fixed-duration ibrutinib plus venetoclax (ibr+ven) versus chlorambucil plus obinutuzumab (clb+o): The Glow study. ASH 2022;Abstract 93.
Ryan CE et al. Updated results from a multicenter, phase 2 study of acalabrutinib, venetoclax, obinutuzumab (AVO) in a population of previously untreated patients with CLL enriched for high-risk disease. ASH 2022;Abstract 344.
Seymour JF et al. Assessing the burden of adverse events in a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia (CLL). ASH 2022;Abstract 3133.
Tausch E et al. Genetic markers and front line FCR/BR vs. rve, gve and give treatment – Outcome results from the CLL13/GAIA trial. ASH 2022;Abstract 345.